UNSPSC 51151670: Tuamine or tuaminoheptane

This classification denotes an amine with the molecular formula C7H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z0420GYD84, chemically known as hexylamine, 1-methyl- but generally known as tuaminoheptane, which bears US NIH Compound Identifier 5603. European Medicines Agency schedules Tuaminoheptane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11360MIG. World Health Organization schedules tuaminoheptane in its Anatomical Therapeutic Chemical (ATC) Classification.

TUAMINOHEPTANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: NC(CCCCC)C.

UNSPSC 51151670 Tuamine or tuaminoheptane is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally describes a specific chemical compound, but the two recent opportunities tagged under it—Seminole County's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs—involve pharmaceuticals and pharmacy benefit management rather than tuamine or tuaminoheptane itself. State and local governments soliciting under this code are primarily health and human services agencies addressing opioid response and pharmacy program administration, not chemical supply or ingredient procurement. The Seminole County opportunity represents a straightforward pharmaceutical acquisition for community health support, while the Texas HHS RFI represents exploratory market research into prescription fulfillment models rather than a product purchase.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida issued an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—note the source contains a date inconsistency suggesting the Florida opportunity predates the 2026 posting date. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; this was exploratory market intelligence gathering rather than a formal solicitation with award intent. The code shows little recent activity reflecting its nominal scope, and business development professionals should verify whether tuamine or tuaminoheptane appears in actual state and local pharmaceutical, health, or chemical procurement channels before committing resources under this classification.